Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
13.95
-0.83 (-5.62%)
Mar 31, 2025, 9:55 AM EDT - Market open
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 37.57, with a low estimate of 24 and a high estimate of 87. The average target predicts an increase of 169.32% from the current stock price of 13.95.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Denali Therapeutics stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 7 | 7 | 7 | 8 |
| Buy | 3 | 3 | 3 | 5 | 5 | 7 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 13 | 13 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +100.72% | Mar 10, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $41 → $33 | Buy | Initiates | $41 → $33 | +136.56% | Mar 7, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $38 → $35 | Strong Buy | Reiterates | $38 → $35 | +150.90% | Mar 5, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $50 → $42 | Buy | Maintains | $50 → $42 | +201.08% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $87 | Strong Buy | Maintains | $80 → $87 | +523.66% | Feb 28, 2025 |
Financial Forecast
Revenue This Year
26.33M
Revenue Next Year
157.19M
from 26.33M
Increased by 497.02%
EPS This Year
-3.09
from -2.57
EPS Next Year
-2.52
from -3.09
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 131.3M | 567.4M | 1.2B | ||
| Avg | 26.3M | 157.2M | 355.4M | ||
| Low | n/a | 15.2M | 78.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,055.1% | 654.5% | ||
| Avg | - | 497.0% | 126.1% | ||
| Low | - | -42.2% | -50.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.32 | -0.61 | 1.76 | ||
| Avg | -3.09 | -2.52 | -0.75 | ||
| Low | -3.61 | -3.59 | -2.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.